OUR THERAPEUTICS
Advancing Precision Therapeutics
Ariel is pioneering breakthrough treatments for complex diseases through precision medicine and targeted therapeutic approaches.
APM-176: A Phase 2 Ready Asset
Leading enterprise software business spins off high-value therapeutic assets with multi-billion dollar revenue potential.
Type: Oral Small Molecule
Target: Increasing CFTR Function (e.g., 28M CRS patients)
Status: Phase 2 Ready
Safety: Phase 1 Complete and De-Risked (N=88)
The Strategic Bridge: From Data to Drugs
Discovery: Identify novel druggable targets.
Acceleration: Rapid patient stratification.
Moat: Proprietary data that fuels a 'Pipeline in a pill'.
Development Pipeline
Our pipeline approach applies diverse therapeutics in various stages of development.
ARIEL-APM -176 Oral
Respiratory Disease Program
Targeting mucus and inflammation.
Phase II Ready
ARIEL-APM -176 Oral
Digestive and Metabolic Disease
Phase II Ready
ARIEL-APM -176 Intra-nasal
Respiratory Disease Program
Preclinical
Future Expansion: A Platform for Proprietary Discovery
ADVANCE
Data Engine
Digestive Disorders
Pancreas IBS/IBD
Liver Disorders
Cirrhosis, NASH
Inflammation/Fibrosis
Systemic Applications
CRS, Bronchiectasis, Asthma, COPD
Respiratory Disorders
Our Innovation Approach
Data-Driven Discovery — Leveraging AI and machine learning to identify novel therapeutic targets and biomarkers based on genetics and systems biology.
Precision Design — Developing treatments calibrated to specific patient populations based on genetic and molecular profiles.
Patient-Centric Focus — Guiding every therapeutic development decision around patient safety, efficacy, and quality of life.